Acute Crit Care.
2024 Nov;39(4):652-653. 10.4266/acc.2023.00983.e1.
Corrigendum to: Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study
- Affiliations
-
- 1Department of Anaesthesiology, All India Institute of Medical Sciences (AIIMS) Patna, Patna, India
- 2Department of Anaesthesiology, All India Institute of Medical Sciences (AIIMS) Bhubaneswar, Bhubaneswar, India
- 3Department of Anaesthesiology, Acharya Harihar Post Graduate Institute of Cancer, Cuttack, India
- KMID: 2563556
- DOI: http://doi.org/10.4266/acc.2023.00983.e1
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study
- Severe acute respiratory distress syndrome caused by SARS-CoV-2 in a pediatric patient, successfully treated with corticosteroids, remdesivir, and tocilizumab: a case report
- Risk of Stroke in COVID-19 Survivors With Asthma: A Nationwide, Population-Based Cohort Study
- Clinical impacts of COVID-19 on severe exacerbation and mortality in interstitial lung disease: prognosis 30 days after infection
- Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19
